Effect of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer.

Abstract

To evaluate whether all-trans-retinoic acid (ATRA) is able to modulate the hemostatic system in patients with solid tumors, we studied patients with locally advanced breast cancer who were enrolled in a Phase Ib study of ATRA +/- Tamoxifen (Tam). In this study, two groups of 15 patients/each were treated for 21 days before operation with ATRA at three doses (15, 45, or 75 mg/m(2)/day on alternate days) given alone (group 1) or in combination with Tam (group 2). One additional group received Tam alone. Plasma samples were evaluated for hypercoagulation markers (FVIIa, F1+2, TAT, D-dimer), fibrinolysis proteins (t-PA, PAI-1), and coagulation inhibitors (protein C, AT). At baseline, cancer patients had FVIIa, F1+2, TAT, and PAI-1 significantly greater than control subjects. During treatment, in the patients given ATRA alone, hypercoagulation markers appeared unmodified. Instead, subjects given Tam alone had a significant elevation of FVIIa, F1+2, and TAT versus baseline. However, in the ATRA + Tam groups, hypercoagulation markers were decreased compared with Tam alone. These results suggest that in selected conditions, pre-operative ATRA may modulate the hypercoagulable state of breast cancer patients.

• Authors: Anna Falanga, S Toma, M Marchetti, R Palumbo, P Raffo, R Consonni, S Marziali, G Dastoli, T Barbui
• Journal: American journal of hematology (Am J Hematol) Vol. 70 Issue 1 Pg. 9-15 (May 2002) ISSN: 0361-8609 [Print] United States
• PMID: 11994976 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Controlled Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2002 Wiley-Liss, Inc.

Chemical References

• Antineoplastic Agents
• Antineoplastic Agents, Hormonal
• Biomarkers
• Tamoxifen
• Tretinoin
• Tissue Plasminogen Activator

Topics

• Aged
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Antineoplastic Agents, Hormonal (administration & dosage, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Biomarkers (blood)
• Breast Neoplasms (blood, drug therapy)
• Dose-Response Relationship, Drug
• Female
• Humans
• Middle Aged
• Prospective Studies
• Tamoxifen (administration & dosage, therapeutic use)
• Thrombophilia (drug therapy)
• Tissue Plasminogen Activator (blood)
• Tretinoin (administration & dosage, therapeutic use)